Drugs / K40b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01137630 | Feb → May 2007 | seborrheic dermatitis | Moberg Pharma AB | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K40b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01137630 ↗ |
| Route | Topical | “K40b is to be applied to affected areas of the scalp” NCT01137630 ↗ |